Dihydroergotamine

FDA Drug Profile

Dihydroergotamine is listed in the FDA National Drug Code directory with 1 NDC code. Available dosage form: powder.

Drug Details

Generic Name
Dihydroergotamine
Brand Names
N/A
Application Number
Sponsor
Teva Czech Industries s.r.o
NDC Codes
1
Dosage Forms
POWDER
Routes
N/A
Active Ingredients
DIHYDROERGOTAMINE

Indications and Usage

1 INDICATIONS AND USAGE ATZUMI is indicated for the acute treatment of migraine with or without aura in adults. ATZUMI is an ergotamine derivative indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use ATZUMI is not indicated for the preventive treatment of migraine or for the management of hemiplegic migraine or migraine with brainstem aura. ( 1 ) Limitations of Use ATZUMI is not indicated for the preventive treatment of migraine. ATZUMI is not indicated for the management of hemiplegic migraine or migraine with brainstem aura.